MetaCap

BioNexus Gene Lab (BGLC) vs Exagen (XGN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Exagen is the larger company by market cap ($92.1 million vs $2.0 million), about 46.2 times the size. Exagen converts more of its revenue into profit, with a net margin of -30.0% versus -40.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BGLC-49.25%XGN-56.51%
+8%-26%-60%
Oct 7, 20261 yearNov 20, 2026
BGLC-47.29%XGN-57.13%
+5%-28%-60%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BGLC versus XGN key metrics
MetricBGLCXGN
Share price$0.68$3.61
Market cap$1.99M$92.10M
1-day change0.00%-5.00%
YTD return—-40.63%
1-year return—-52.56%
5-year return—-67.24%
EPS (TTM)$-1.26$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.42M$66.58M
Revenue growth (YoY)-21.93%+19.65%
Net income (latest FY)$-2.98M$-19.95M
Gross margin14.62%58.28%
Operating margin-39.93%-21.13%
Net margin-40.20%-29.97%
52-week high$4.97$9.22
52-week low$0.621$2.59
Distance from 52-week high-86.32%-60.85%
Analyst consensus—strong_buy
Avg. price target upside—+185.04%
Average volume6.70K470.43K
Shares outstanding2.93M25.51M
Employees19216
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Exagen is about 46.2 times larger than BioNexus Gene Lab by market value ($92.10M vs $1.99M).
  • Exagen is more profitable, keeping -30.0 cents of every revenue dollar as net income versus -40.2 cents for BioNexus Gene Lab.
  • Exagen grew revenue faster in its latest fiscal year (+19.65% vs -21.93%).

About BioNexus Gene Lab

BGLC stock →

BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.

Health Care · Medical Specialities · 19 employees

About Exagen

XGN stock →

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States.

Health Care · Medical Specialities · 216 employees

BGLC vs XGN FAQ

Which is bigger, BioNexus Gene Lab or Exagen?

Exagen (XGN) is larger, with a market capitalization of $92.10M compared with $1.99M for BioNexus Gene Lab (BGLC).

Are BioNexus Gene Lab and Exagen in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons